These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21147500)

  • 1. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
    Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
    Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
    Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
    Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
    Leach JC; Wang A; Ye K; Jin S
    Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles.
    Yu MK; Kim D; Lee IH; So JS; Jeong YY; Jon S
    Small; 2011 Aug; 7(15):2241-9. PubMed ID: 21648076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
    Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
    Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
    Tang L; Tong R; Coyle VJ; Yin Q; Pondenis H; Borst LB; Cheng J; Fan TM
    ACS Nano; 2015 May; 9(5):5072-81. PubMed ID: 25938427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
    Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
    Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
    Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
    Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic.
    Pearce AK; Simpson JD; Fletcher NL; Houston ZH; Fuchs AV; Russell PJ; Whittaker AK; Thurecht KJ
    Biomaterials; 2017 Oct; 141():330-339. PubMed ID: 28711780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
    Kim D; Jeong YY; Jon S
    ACS Nano; 2010 Jul; 4(7):3689-96. PubMed ID: 20550178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates.
    Lee IH; An S; Yu MK; Kwon HK; Im SH; Jon S
    J Control Release; 2011 Nov; 155(3):435-41. PubMed ID: 21641946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex.
    Kim E; Jung Y; Choi H; Yang J; Suh JS; Huh YM; Kim K; Haam S
    Biomaterials; 2010 Jun; 31(16):4592-9. PubMed ID: 20206379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer cells using an RNA/peptide dual-aptamer probe.
    Min K; Song KM; Cho M; Chun YS; Shim YB; Ku JK; Ban C
    Chem Commun (Camb); 2010 Aug; 46(30):5566-8. PubMed ID: 20407731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
    Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
    Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
    Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
    J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
    Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
    J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).
    Patil Y; Shmeeda H; Amitay Y; Ohana P; Kumar S; Gabizon A
    Nanomedicine; 2018 Jun; 14(4):1407-1416. PubMed ID: 29680672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PSMA-targeted doxorubicin small-molecule drug conjugate.
    Yoon H; Savoy EA; Mesbahi N; Hendricksen AT; March GL; Fulton MD; Backer BS; Berkman CE
    Bioorg Med Chem Lett; 2024 May; 104():129712. PubMed ID: 38521177
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.